“Triple” Reuptake Inhibitor(TPI’s) The Next Generation Of Antidepressants

               

             Depression has been associated with impaired neurotransmission of serotonergic, norepinephrinergic, and dopaminergic pathways, although most pharmacologic treatment strategies for depression enhance only serotonin and norepinephrine neurotransmission. “Triple” Reuptake Inhibitor new class of antidepressants which inhibit the reuptake of all three neurotransmitters in the hope of creating medications with broader efficacy and/or quicker onset of action.       

           It has been hypothesized that a broad-spectrum antidepressant will produce a more rapid onset and better efficacy than agents inhibiting the reuptake of serotonin and/or norepinephrine, in part due to the addition of the dopamine component. Triple reuptake inhibitors (serotonin, norepinephrine, and dopamine reuptake inhibitors) are being developed as a new class of antidepressant.

Developing Triple Reuptake Inhibitors

Although the clinical efficacy of such a broad-spectrum antidepressant has not yet been fully demonstrated, several compounds have entered clinical trials, such as DOV -216,303, DOV 21,947, NS-2359, and SEP-225289. 

REFERENCE

1.Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidenc

2. Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their

3. Richelson E. Action of antidepressant and other drugs on norepinephrine systems. In: Ordway GA, Schwartz

4. Baldessarini R. Drugs and the treatment of psychiatric disorders-depression and mania. In: Hardman JG,

AJMAL M

FIRST YEAR M PHARM

ALSHIFA COLLEGE OF PHARMACY